ℹ️
🇬🇧
Search
Search for publications relevant for "trastuzumab emtansine"
trastuzumab emtansine
Publication
Class
Person
Publication
Programmes
publication
Pharmacological profile – trastuzumab emtansine
2022 |
Third Faculty of Medicine
publication
Trastuzumab emtansine in the treatment of residual HER2-positive breast cancer
2019 |
First Faculty of Medicine
publication
Report of University Hospital Hradec Králové to the clinical trial protocol No: BO27938
Publication without faculty affiliation
publication
Research Report University Hospital of the clinical trial BO27938
Publication without faculty affiliation
publication
Experience in the treatment of advanced HER2 positive breast tumor in University Hospital in Motol
2016 |
Publication without faculty affiliation
publication
News in anti-HER2 targeted therapy in breast cancer
+1
2013 |
First Faculty of Medicine
publication
Trastuzumab emtansin v léčbě časného karcinomu prsu
2021 |
First Faculty of Medicine
publication
Final report of University Hospital Hradec Kralove to the clinical trial protocol no. Final report of University Hospital Hradec Kralove to the clinical trial protocol no. BO28407
Publication without faculty affiliation
publication
Overview of biological therapy for HER2-positive metastatic breast cancer
2015 |
First Faculty of Medicine, Faculty of Physical Education and Sport
publication
Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysis
Publication without faculty affiliation
publication
Research Report University Hospital clinical trial BO28407
Publication without faculty affiliation
publication
Report of University Hospital Hradec Králové to the clinical trial protocol No: BO28407
Publication without faculty affiliation
publication
Complete and long-term response of HER2 positive locally highly advanced metastatic breast cancer - case report
2019 |
Third Faculty of Medicine
publication
Trastuzumab deruxtecan: strong player in the field of metastatic HER2 positive breast cancer
2022 |
First Faculty of Medicine
publication
Personalization of neo/adjuvant treatment of HER2-positive breast cancer is the key to achieve the best results
2022 |
First Faculty of Medicine
publication
Treatment of HER2-positive breast cancer in 2020
2020 |
First Faculty of Medicine
publication
Skupina léků anti-HER2 pro pacientky s karcinomu prsu se rozrostla o preparát Phesgo
2021 |
First Faculty of Medicine
publication
Summary of the 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Prepared by the Czech Society of Cardiology
2017 |
Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
publication
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE
2021 |
First Faculty of Medicine